These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38924379)

  • 1. Perspective of Dutch Patients with Gout on Continuation or Discontinuation of Urate-Lowering Therapy During Remission: A Mixed-Methods Study.
    Peeters IR; Veenstra F; Wanten SAC; Vriezekolk JE; van den Ende CH; den Broeder AA; van Herwaarden N; Verhoef LM; Flendrie M
    Arthritis Care Res (Hoboken); 2024 Jun; ():. PubMed ID: 38924379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial.
    Peeters IR; den Broeder AA; Taylor WJ; den Broeder N; Flendrie M; van Herwaarden N
    Trials; 2023 Apr; 24(1):282. PubMed ID: 37072799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review.
    Beslon V; Moreau P; Maruani A; Maisonneuve H; Giraudeau B; Fournier JP
    J Gen Intern Med; 2018 Mar; 33(3):358-366. PubMed ID: 29204974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients.
    Te Kampe R; Boonen A; Jansen T; Janssen M; de Vries H; van Durme C
    RMD Open; 2022 Feb; 8(1):. PubMed ID: 35185008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study.
    Singh JA
    Arthritis Res Ther; 2014 Mar; 16(2):R82. PubMed ID: 24678765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beliefs of rheumatologists and general practitioners on urate lowering therapy: a cross-sectional study.
    Veenstra F; Vriezekolk JE; van den Bemt BJF; Schers HJ; Sloot B; van den Ende CHM; van Herwaarden N; Flendrie M
    Rheumatol Adv Pract; 2023; 7(2):rkad033. PubMed ID: 37113501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reasons for discontinuing urate-lowering treatment in community-dwelling adults with gout: results of a primary care-based cross-sectional study.
    Elmelegy D; Abhishek A
    Rheumatol Adv Pract; 2021; 5(2):rkab022. PubMed ID: 34131622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical efficacy of urate-lowering therapy in acute gout: a meta-analysis of randomized controlled trials.
    Zhang X; Tang Y; Wang M; Wang D; Li Q
    Clin Rheumatol; 2021 Feb; 40(2):701-710. PubMed ID: 32562072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England.
    Russell MD; Roddy E; Rutherford AI; Ellis B; Norton S; Douiri A; Gulliford MC; Cope AP; Galloway JB
    Rheumatology (Oxford); 2023 Jul; 62(7):2426-2434. PubMed ID: 36355461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation.
    Holladay EE; Mudano AS; Xie F; Zhang J; Mikuls TR; LaMoreaux B; Padnick-Silver L; Curtis JR
    Arthritis Res Ther; 2024 Apr; 26(1):86. PubMed ID: 38609967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy.
    Pascart T; Latourte A; Flipo RM; Chalès G; Coblentz-Baumann L; Cohen-Solal A; Ea HK; Grichy J; Letavernier E; Lioté F; Ottaviani S; Sigwalt P; Vandecandelaere G; Richette P; Bardin T
    Joint Bone Spine; 2020 Oct; 87(5):395-404. PubMed ID: 32422338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of gout following 2016/2017 European (EULAR) and British (BSR) guidelines: An interrupted time-series analysis in the United Kingdom.
    Russell MD; Rutherford AI; Ellis B; Norton S; Douiri A; Gulliford MC; Cope AP; Galloway JB
    Lancet Reg Health Eur; 2022 Jul; 18():100416. PubMed ID: 35814340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
    Janssen CA; Oude Voshaar MAH; Ten Klooster PM; Vonkeman HE; van de Laar MAFJ
    Clin Rheumatol; 2019 Aug; 38(8):2233-2239. PubMed ID: 31030363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global patterns of treat-to-serum urate target care for gout: Systematic review and meta-analysis.
    Son CN; Stewart S; Su I; Mihov B; Gamble G; Dalbeth N
    Semin Arthritis Rheum; 2021 Aug; 51(4):677-684. PubMed ID: 34139520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cohort study investigating gout flares and management in UK general practice.
    Finnikin S; Mallen CD; Roddy E
    BMC Prim Care; 2023 Nov; 24(1):246. PubMed ID: 37993770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout.
    Richardson JC; Liddle J; Mallen CD; Roddy E; Hider S; Prinjha S; Ziebland S
    BMC Musculoskelet Disord; 2016 Jun; 17():249. PubMed ID: 27267878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regular pre-admission urate-lowering therapy and serum urate testing are associated with a shorter hospital length of stay in people with gout: A nation-wide population-based cohort study.
    Jatuworapruk K; Grainger R; Dalbeth N; Taylor WJ
    Int J Rheum Dis; 2022 Feb; 25(2):154-162. PubMed ID: 34796661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cross-sectional internet-based patient survey of the management strategies for gout.
    Singh JA; Shah N; Edwards NL
    BMC Complement Altern Med; 2016 Mar; 16():90. PubMed ID: 26931313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
    Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
    Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients.
    van de Laar CJ; Janssen CA; Janssen M; Oude Voshaar MAH; Al MJ; van de Laar MAFJ
    PLoS One; 2022; 17(1):e0261940. PubMed ID: 35089941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.